Revolutionizing Cytokine Therapies Through Overcoming Barriers in Toxicity, Delivery, Specificity & Translation
Welcome to the only in person dedicated industry forum supporting the development of robust cytokine-based cancer immunotherapy platforms (cytokine muteins, antibody-cytokine fusion proteins (immunokines), anticancer vaccines, and cancer-directed antibodies) to deliver targeted, durable therapeutic interventions to solid tumor and hematological cancer indications.
This comprehensive, drug development focused agenda will showcase the latest concepts and molecular engineering approaches being utilized by biopharma and research groups to help you overcome the challenges in:
- Toxicity management - engineering selectivity, targeting and half life modulation
- Optimizing the risk benefit by dose and schedule optimization
- Achieving safe and acceptable delivery
- Understanding the potentials for combination
- Delving into the clinical data to understand the translational side
You will have the opportunity to join a pre-conference workshop day exploring pre-clinical models for cytokine research and the world of cytokines in inflammatory disease, providing insight into where the world of cytokine research is going beyond oncology.
Join this exclusive community of cytokine pioneers to network and learn from the leading experts in pharma, biotech and academia, as we discuss how to successfully and safely deliver cytokine therapies to a plethora of cancer indications.
Across 3 content packed days, 24+ experts will converge to discuss novel cytokines, the shortfalls of these therapies and how to learn from the pitfalls of the first cytokine era – this is not one to miss!